近期病原體表明需要改進的情境意識能力，例如 Co-Dx PCR 現場檢測平台所提供的能力
緊隨埃博拉疫情爆發和世界衞生組織緊急聲明，以及增強的疾病控制與預防中心旅行者篩查措施
, /PRNewswire/ -- Co-Diagnostics, Inc.（納斯達克：CODX）（&#34;Co-Dx&#34; 或 &#34;公司&#34;），是一家擁有獨特專利平台的分子診斷公司，專注於分子診斷測試的開發，今天宣佈已完成針對目前在剛果民主共和國和烏干達引發埃博拉疫情的 Bundibugyo 病毒（&#34;BDBV&#34;）的檢測開發策略。
&#34;我們很高興地報告，我們已完成 BDBV 的檢測開發策略，如果出現需要該檢測的情況，我們預計能夠迅速執行該策略並使測試可用，&#34; Co-Diagnostics 首席執行官 Dwight Egan 説。&#34;除了快速、黃金標準 PCR 診斷在識別感染患者和幫助限制埃博拉等致命疾病傳播方面的作用外，我們認為近期事件還強調了去中心化診斷和實時情境意識在幫助公共衞生當局追蹤和控制疫情中的日益重要性。&#34;
5 月 17 日，世界衞生組織宣佈由 BDBV 引起的埃博拉疫情為國際關注的公共衞生緊急事件（&#34;PHEIC&#34;）。截至 5 月 17 日，剛果民主共和國報告了 8 例實驗室確診病例、246 例疑似病例和 80 例疑似死亡病例，烏干達則報告了 2 例實驗室確診病例和 1 例死亡病例。
該公告還跟隨美國疾病控制與預防中心（&#34;CDC&#34;）關於增強來自埃博拉疫情影響地區的旅行者篩查和監測措施的最新指導。根據 CDC 的説法，這些措施包括增加旅行者監測、接觸追蹤協調和增強醫院準備工作，強調了快速檢測和實時疫情可見性在應對新興傳染病威脅中的重要性。
Egan 先生補充道，&#34;COVID-19 大流行強化了對新興傳染病威脅的準備和快速響應能力的重要性，我們認為在這些情況出現時迅速響應是非常重要的。我們設計 Co-Dx PCR 平台 * 時考慮了這些需求，包括支持去中心化檢測和雲連接架構的能力。實時瞭解疫情活動可以在幫助公共衞生當局識別、監測和應對新興傳染病威脅方面發揮重要作用。我們期待與政府和非政府機構及組織在未來開發該檢測方面的合作，視需要而定。&#34;
*Co-Dx PCR 平台（包括 PCR Home®、PCR Pro®、移動應用程序及所有相關測試）正在接受 FDA 和/或其他監管機構的審查，目前尚未上市銷售。
關於 Co-Diagnostics, Inc.: Co-Diagnostics, Inc. 是一家位於猶他州的分子診斷公司，開發、製造和銷售先進的診斷技術。公司的技術用於設計基於核酸分子（DNA 或 RNA）檢測和/或分析的測試。公司還利用其專有技術為其 Co-Dx PCR 家庭和現場檢測平台（正在接受監管審查，尚未上市銷售）設計特定測試，並識別用於其他應用的遺傳標記。
前瞻性聲明： 本新聞稿包含 1995 年《私人證券訴訟改革法案》意義上的前瞻性聲明。前瞻性聲明可以通過諸如 “相信”、“期望”、“估計”、“打算”、“可能”、“計劃”、“將”、“尋求”、“預期” 等詞語或這些詞的否定形式來識別。本新聞稿中的前瞻性聲明包括但不限於以下內容：(i) 公司執行其 Bundibugyo 病毒（“BDBV”）檢測開發戰略的能力；(ii) BDBV 檢測的潛在未來開發、驗證、監管審查、商業化、生產和分發；(iii) 公司快速應對新興傳染病威脅的能力；(iv) Co-Dx PCR 平台在去中心化診斷和疫情監測中的潛在效用、有效性和採用；(v) 實時態勢感知和雲連接診斷系統在公共衞生應對工作中的潛在作用；(vi) 與政府和非政府組織在傳染病準備和應對方面的潛在合作。這些聲明面臨許多風險和不確定性，包括但不限於：市場需求或公共衞生狀況可能發生變化的風險；與公司成功開發、驗證、獲得監管授權或批准、生產和商業化任何 BDBV 檢測或相關產品的能力相關的風險；與 FDA 或其他監管機構的監管審查相關的風險；與 Co-Dx PCR 平台的性能、可靠性和市場接受度相關的風險；與對第三方、供應商、合作伙伴和分銷商的依賴相關的風險；與競爭、技術變革和知識產權保護相關的風險； 以及公司不時在向證券交易委員會（“SEC”）提交的文件中描述的其他風險。實際結果可能與這些前瞻性聲明中表達或暗示的結果有實質性差異。提醒讀者不要對前瞻性聲明過度依賴。有關風險和不確定性的進一步描述可以在公司於 2026 年 3 月 31 日向證券交易委員會提交的 10-K 表格年度報告及其其他 SEC 文件中找到。除非適用法律要求，公司沒有義務更新任何前瞻性聲明，以反映本新聞稿日期後的事件或情況。
來源 Co-Diagnostics
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3"/>

CODX

Co-Diagnostics, Inc. 在剛果民主共和國和烏干達最近的埃博拉疫情後，開發了一種針對 Bundibugyo 病毒（BDBV）的檢測策略。該公司強調快速 PCR 診斷和實時情況意識在應對傳染病威脅中的重要性。隨着世界衞生組織宣佈此次疫情為公共衞生緊急事件，Co-Diagnostics 旨在與衞生當局合作，以確保應對準備和快速反應能力

Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
<div class="lb-trans">近期病原體表明需要改進的情境意識能力，例如 Co-Dx PCR 現場檢測平台所提供的能力
</div>Follows outbreak of Ebola and WHO emergency declaration, and enhanced CDC traveler screening measures
<div class="lb-trans">緊隨埃博拉疫情爆發和世界衞生組織緊急聲明，以及增強的疾病控制與預防中心旅行者篩查措施
</div>, /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (&#34;Co-Dx&#34; or &#34;the Company&#34;), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has completed the assay development strategy for the Bundibugyo virus (&#34;BDBV&#34;) currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda.
<div class="lb-trans">, /PRNewswire/ -- Co-Diagnostics, Inc.（納斯達克：CODX）（&#34;Co-Dx&#34; 或 &#34;公司&#34;），是一家擁有獨特專利平台的分子診斷公司，專注於分子診斷測試的開發，今天宣佈已完成針對目前在剛果民主共和國和烏干達引發埃博拉疫情的 Bundibugyo 病毒（&#34;BDBV&#34;）的檢測開發策略。
</div>&#34;We are pleased to report that we have completed the assay development strategy for BDBV, and should a situation arise requiring the assay, we expect we would be well positioned to execute the strategy and rapidly make the test available,&#34; said Dwight Egan, Co-Diagnostics Chief Executive Officer. &#34;In addition to the role that rapid, gold-standard PCR diagnostics can play in identifying infected patients and helping limit the spread of deadly diseases like Ebola, we believe recent events also underscore the growing importance of decentralized diagnostics and real-time situational awareness in helping public health authorities track and contain outbreaks.&#34;
<div class="lb-trans">&#34;我們很高興地報告，我們已完成 BDBV 的檢測開發策略，如果出現需要該檢測的情況，我們預計能夠迅速執行該策略並使測試可用，&#34; Co-Diagnostics 首席執行官 Dwight Egan 説。&#34;除了快速、黃金標準 PCR 診斷在識別感染患者和幫助限制埃博拉等致命疾病傳播方面的作用外，我們認為近期事件還強調了去中心化診斷和實時情境意識在幫助公共衞生當局追蹤和控制疫情中的日益重要性。&#34;
</div>On May 17, WHO declared an outbreak of Ebola disease caused by BDBV as a public health emergency of international concern (&#34;PHEIC&#34;). As of May 17, eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths have been reported in the Democratic Republic of the Congo, along with two laboratory-confirmed cases and one reported death in Uganda.
<div class="lb-trans">5 月 17 日，世界衞生組織宣佈由 BDBV 引起的埃博拉疫情為國際關注的公共衞生緊急事件（&#34;PHEIC&#34;）。截至 5 月 17 日，剛果民主共和國報告了 8 例實驗室確診病例、246 例疑似病例和 80 例疑似死亡病例，烏干達則報告了 2 例實驗室確診病例和 1 例死亡病例。
</div>The announcement also follows recent guidance from the U.S. Centers for Disease Control and Prevention (&#34;CDC&#34;) regarding enhanced screening and monitoring measures for travelers arriving from regions impacted by Ebola outbreaks. According to the CDC, these measures include increased traveler monitoring, contact tracing coordination, and enhanced hospital preparedness efforts, underscoring the importance of rapid testing and real-time outbreak visibility in responding to emerging infectious disease threats.
<div class="lb-trans">該公告還跟隨美國疾病控制與預防中心（&#34;CDC&#34;）關於增強來自埃博拉疫情影響地區的旅行者篩查和監測措施的最新指導。根據 CDC 的説法，這些措施包括增加旅行者監測、接觸追蹤協調和增強醫院準備工作，強調了快速檢測和實時疫情可見性在應對新興傳染病威脅中的重要性。
</div>Mr. Egan added, &#34;The COVID-19 pandemic reinforced the importance of preparedness and rapid response capabilities for emerging infectious disease threats, and we believe it is important to be positioned to respond quickly as we have in the past when situations like these have emerged. We designed the Co-Dx PCR platform* with these types of needs in mind, including the ability to support decentralized testing and cloud-connected architecture. Real-time visibility into outbreak activity can play an important role in helping public health authorities identify, monitor, and respond to emerging infectious disease threats. We look forward to collaboration with governmental and non-governmental agencies and organizations on the future development of this test, as needed.&#34;
<div class="lb-trans">Egan 先生補充道，&#34;COVID-19 大流行強化了對新興傳染病威脅的準備和快速響應能力的重要性，我們認為在這些情況出現時迅速響應是非常重要的。我們設計 Co-Dx PCR 平台 * 時考慮了這些需求，包括支持去中心化檢測和雲連接架構的能力。實時瞭解疫情活動可以在幫助公共衞生當局識別、監測和應對新興傳染病威脅方面發揮重要作用。我們期待與政府和非政府機構及組織在未來開發該檢測方面的合作，視需要而定。&#34;
</div>*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
<div class="lb-trans">*Co-Dx PCR 平台（包括 PCR Home®、PCR Pro®、移動應用程序及所有相關測試）正在接受 FDA 和/或其他監管機構的審查，目前尚未上市銷售。
</div>About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
<div class="lb-trans">關於 Co-Diagnostics, Inc.: Co-Diagnostics, Inc. 是一家位於猶他州的分子診斷公司，開發、製造和銷售先進的診斷技術。公司的技術用於設計基於核酸分子（DNA 或 RNA）檢測和/或分析的測試。公司還利用其專有技術為其 Co-Dx PCR 家庭和現場檢測平台（正在接受監管審查，尚未上市銷售）設計特定測試，並識別用於其他應用的遺傳標記。
</div>Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as &#34;believes,&#34; &#34;expects,&#34; &#34;estimates,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;plans,&#34; &#34;will,&#34; &#34;seeks,&#34; &#34;anticipates,&#34; and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: (i) the Company's ability to execute its assay development strategy for Bundibugyo virus (&#34;BDBV&#34;); (ii) the potential future development, validation, regulatory review, commercialization, manufacture, and distribution of a BDBV test; (iii) the Company's ability to rapidly respond to emerging infectious disease threats; (iv) the potential utility, effectiveness, and adoption of the Co-Dx PCR platform for decentralized diagnostics and outbreak monitoring; (v) the potential role of real-time situational awareness and cloud-connected diagnostic systems in public health response efforts; and (vi) potential collaborations with governmental and non-governmental organizations relating to infectious disease preparedness and response. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks related to the Company's ability to successfully develop, validate, obtain regulatory authorization or approval for, manufacture, and commercialize any BDBV assay or related products; risks related to regulatory review by the FDA or other regulatory authorities; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission (&#34;SEC&#34;). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
<div class="lb-trans">前瞻性聲明： 本新聞稿包含 1995 年《私人證券訴訟改革法案》意義上的前瞻性聲明。前瞻性聲明可以通過諸如 “相信”、“期望”、“估計”、“打算”、“可能”、“計劃”、“將”、“尋求”、“預期” 等詞語或這些詞的否定形式來識別。本新聞稿中的前瞻性聲明包括但不限於以下內容：(i) 公司執行其 Bundibugyo 病毒（“BDBV”）檢測開發戰略的能力；(ii) BDBV 檢測的潛在未來開發、驗證、監管審查、商業化、生產和分發；(iii) 公司快速應對新興傳染病威脅的能力；(iv) Co-Dx PCR 平台在去中心化診斷和疫情監測中的潛在效用、有效性和採用；(v) 實時態勢感知和雲連接診斷系統在公共衞生應對工作中的潛在作用；(vi) 與政府和非政府組織在傳染病準備和應對方面的潛在合作。這些聲明面臨許多風險和不確定性，包括但不限於：市場需求或公共衞生狀況可能發生變化的風險；與公司成功開發、驗證、獲得監管授權或批准、生產和商業化任何 BDBV 檢測或相關產品的能力相關的風險；與 FDA 或其他監管機構的監管審查相關的風險；與 Co-Dx PCR 平台的性能、可靠性和市場接受度相關的風險；與對第三方、供應商、合作伙伴和分銷商的依賴相關的風險；與競爭、技術變革和知識產權保護相關的風險； 以及公司不時在向證券交易委員會（“SEC”）提交的文件中描述的其他風險。實際結果可能與這些前瞻性聲明中表達或暗示的結果有實質性差異。提醒讀者不要對前瞻性聲明過度依賴。有關風險和不確定性的進一步描述可以在公司於 2026 年 3 月 31 日向證券交易委員會提交的 10-K 表格年度報告及其其他 SEC 文件中找到。除非適用法律要求，公司沒有義務更新任何前瞻性聲明，以反映本新聞稿日期後的事件或情況。
</div>SOURCE Co-Diagnostics
<div class="lb-trans">來源 Co-Diagnostics
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA62707&amp;Transmission_Id=202605190900PR_NEWS_USPR_____LA62707&amp;DateId=20260519"/>

09:00 ETCo-Diagnostics 在近期全球爆發警報後開發埃博拉檢測策略